Page last updated: 2024-10-27

2,5-dihydroxybenzoic acid and Parkinson Disease, Secondary

2,5-dihydroxybenzoic acid has been researched along with Parkinson Disease, Secondary in 1 studies

2,5-dihydroxybenzoic acid: RN given refers to parent cpd; a oxidative product of saligenin
2,5-dihydroxybenzoic acid : A dihydroxybenzoic acid having the two hydroxy groups at the 2- and 5-positions.

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kondo, T1
Shimada, H1
Hatori, K1
Sugita, Y1
Mizuno, Y1

Other Studies

1 other study available for 2,5-dihydroxybenzoic acid and Parkinson Disease, Secondary

ArticleYear
Talipexole protects dopaminergic neurons from methamphetamine toxicity in C57BL/6N mouse.
    Neuroscience letters, 1998, May-15, Volume: 247, Issue:2-3

    Topics: Animals; Azepines; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Dopamine

1998